2022-10-21

ROI-NJ: BD’s new Onclarity HPV test greatly improves standard of care for women

ROI-NJ: BD’s new Onclarity HPV test greatly improves standard of care for women

Molly Broache, Associate Director, Medical Affairs for US IDS explains how the BD Onclarity™ HPV Assay positively impacts public health by providing a more precise estimate of a woman’s risk of cervical precancer and cancer.

Latest resources

Discover our latest articles, webinars, press releases and updates in women's health.

Molly Broache, Associate Director, Medical Affairs for US IDS discusses the future of cervical cancer screening
Cervical Cancer | News & Updates
Clinical Lab Products: The Future of Cervical Cancer Screening is Here
Contemporary OB/GYN: BD Onclarity™ HPV Assay: What it means for the future of cervical cancer detection
Cervical Cancer | News & Updates
Contemporary OB/GYN: BD Onclarity™ HPV Assay: What it means for the future of cervical cancer detection
Smiling woman smiling while painting
STIs | Vaginitis | Brochures
Vaginitis and STIs: The right treatment begins with the right diagnosis